Perinatal AntiDepressant Exposure alters Cortical Network Function in Rodents

5-HT and Abnormal Brain Development. 5-HT Dysfunction and Autism Spectrum Disorder (ASD)

Perinatal antidepressant exposure alters cortical network function in rodents
Cutting edge news and reports from PNAS, one of the world’s most-cited multidisciplinary scientific journals

Abstract:

Serotonin (5-HT) plays a key role in early brain development, and manipulation of 5-HT levels during this period can have lasting neurobiological and behavioral consequences. It is unclear how perinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts cortical neural network function and what mechanism(s) may elicit the disruption of normal neuronal connections/interactions. In this article, we report on cortical wiring organization after pre- and postnatal exposure to the SSRI citalopram. We show that manipulation of 5-HT during early development in both in vitro and in vivo models disturbs characteristic chemoarchitectural and electrophysiological brain features, including changes in raphe and callosal connections, sensory processing, and myelin sheath formation. Also, drug-exposed rat pups exhibit neophobia and disrupted juvenile play behavior. These findings indicate that 5-HT homeostasis is required for proper brain maturation and that fetal/infant exposure to SSRIs should be examined in humans, particularly those with developmental dysfunction, such as autism.

Full study: Perinatal antidepressant exposure alters cortical network function in rodents, Proceedings of the National Academy of Sciences of the United States of America PNAS, 13 June 2011

Related posts:

Est-ce que ça me perturbe?

La Campagne d’@EDCFree pour un Avenir SANS Perturbateurs Endocriniens Environnementaux

EDC free Europe: comment agir
Soutenez la campagne “EDC free Europe” en quelques étapes simples

Aidez EDC Free Europe à faire savoir aux gouvernements d’Europe que nous voulons un avenir sans PE. Montrez leur que vous vous souciez de la présence de perturbateurs endocriniens dans les produits ou les objets que vous consommez en téléchargeant ou en “likant” une photo que EDC Free Europe fera parvenir aux décideurs.

Voici comment vous impliquer en quelques étapes simples!

  1. Téléchargez la flèche avec le slogan “Est ce que ça me perturbe ?
  2. Dites nous ce qui vous perturbe en désignant à l’aide de la flèche un objet ou produit qui vous préoccupe et prenez une photo !
  3. Mettez la photo en ligne ; elle sera affichée prochainement sur la galerie Flickr.

STILBESTROL 25 mg Tablets by DAGRA NV

Diethylstilbestrol or DES was sold under many names

Stilbestrol - Dagra - 25mg
Diethylstilbestrol or DES was sold under many names

Diethylstilbestrol or DES was sold under many names including Distilbène®, Stilbetin®, Stilboestrol-Borne®, Benzestrol®, Chlorotrianisene®, Estrobene® and Estrosyn® to name just a few. Many different companies manufactured and marketed this drug under more than 200 different brand names.

This glass bottle of Stilbestrol tablets was manufactured by Dagra NV
Amsterdam – Antwerpen – London – Madrid

  • Watch the Diaporama, and the DES drugs photo set on flickr®  DES Diethylstilbestrol's photostream on Flickr
  • If you already have a flickr® account, add us as a contact.
    Email your photos to des.daughter@gmail.com with a short description and title :-)
More DES DiEthylStilbestrol Resources

Vulvar Cancer: the Cancer no One talks about

Darci Picoult personal Essay

I Had the Cancer No One Talks About
Darci Picoult, journalist, DES daughter and author of My Virginia

After a devastating diagnosis and major gynecological surgery transformed author Darci Picoult’s body, she wondered whether anything — her marriage, her sex life, her relationship with her daughters — would ever be the same. It wasn’t. She came through stronger, more outspoken, and more intimately connected to the people she loves.

Read more: Vulvar Cancer Personal Essay, “I Had the Cancer No One Talks About
by Darci Picoult, journalist, DES daughter and author of My Virginia

About DES and Cancer:

More DES DiEthylStilbestrol Resources

Topamax Drug: FDA warned that Topiramate could cause Birth Defects

Elevated risk for cleft lip and cleft palate in babies born to women who took topiramate during pregnancy

FDA Warns That Topiramate Could Cause Birth Defects: What to Tell Patients
Elevated risk for cleft lip and cleft palate in babies born to women who took topiramate during pregnancy

The FDA has issued several warnings about the use of topiramate by childbearing woman based on data from two registries, which showed an increased risk of oral clefts in infants exposed to monotherapy during the first trimester of pregnancy.

The FDA said topiramate would now be classified as a “Pregnancy Category D” drug, meaning there is evidence of human fetal risk based on human data.

Read FDA Warns That Topiramate Could Cause Birth Defects: What to Tell Patients
Neurology Today: 07 April 2011 – Volume 11 – Issue 7 – pp 1,8-9

FDA Safety Information for Patients and Providers:
Topiramate (marketed as Topamax) Information, 03 April 2011

High Bioavailability of Bisphenol A from Sublingual Exposure

BPA can be efficiently and very rapidly absorbed through the oral mucosa after sublingual exposure

High Bioavailability of Bisphenol A from Sublingual Exposure
An NIEHS/NIH journal of research and news on environment and human health

Background:
Bisphenol-A (BPA) risk assessment is currently hindered by the rejection of reported higher-than-expected plasma BPA concentrations in humans after oral ingestion. These are deemed incompatible with the almost complete hepatic first-pass metabolism of BPA into its inactive glucurono-conjugated form, BPA glucuronide (BPAG).

Objectives:
Using dogs as a valid model, we compared plasma concentrations of BPA over a 24-hr period after intravenous, orogastric, and sublingual administration in order to establish the absolute bioavailability of BPA administered sublingually and to compare it with oral bioavailability.

Methods:
Six dogs were sublingually administered BPA at 0.05 mg/kg and 5 mg/kg. We compared the time course of plasma BPA concentrations with that obtained in the same dogs after intravenous administration of the same BPA doses and after a 20-mg/kg BPA dose administrated by orogastric gavage.

Results:
The data indicated that the systemic bioavailability of BPA deposited sublingually was high (70–90%) and that BPA transmucosal absorption from the oral cavity led to much higher BPA internal exposure than obtained for BPA absorption from the gastrointestinal tract. The concentration ratio of BPAG to BPA in plasma was approximately 100-fold lower following sublingual administration than after orogastric dosing, distinguishing the two pathways of absorption.

Conclusions:
Our findings demonstrate that BPA can be efficiently and very rapidly absorbed through the oral mucosa after sublingual exposure. This efficient systemic entry route of BPA may lead to far higher BPA internal exposures than known for BPA absorption from the gastrointestinal tract.

Sources: full report, Environmental Health Perspectives
DOI:10.1289/ehp.1206339, 12 June 2013

Related post: The BPA Safety deeply challenged by a new Discovery

Our tags BPA – Endocrine Disruptors – Pesticides – Phthalates

IVF Babies 65% more likely to develop Leukaemia, 88% more likely to develop Childhood Cancer

Cancer link claimed in ovary fertility drugs

IVF babies 'are a third more likely to develop childhood cancer'
ASRM is a non-profit organization devoted to advancing knowledge and expertise in reproductive medicine including infertility, menopause, and sexuality

Children born from IVF or in vitro fertilization increased risk of developing cancer . Research results of scientists from Denmark indicates that babies born from fertility treatment outcomes 33 percent higher chance of suffering from cancer since she was a childhood .

Types of cancer are also not arbitrary . According to research , these babies are 65 percent greater risk of suffering from blood cancer ( leukemia ) , and 88 percent greater brain cancer and central nervous system .

Abstract

Objective
To clarify the association between fertility treatment and the risk for cancer in children.

Patient(s)
Twenty-five cohort and case-control studies involving children born after fertility treatment as the exposure of interest and cancer as the outcome.

Main Outcome Measure(s)
Medline was searched through September 2012 to identify relevant studies. The study-specific estimates for each cancer outcome were combined into a pooled relative risk (RR) with 95% confidence interval (CI) by a meta-analytic approach.

Result(s)
We found that children born after fertility treatment were at increased risk for all cancers (RR = 1.33; 95% CI, 1.08–1.63) and for hematological cancers (RR = 1.59; 95% CI, 1.32–1.91), central nervous system/neural cancers (RR = 1.88; 95% CI, 1.02–3.46), and other solid cancers (RR = 2.19; 95% CI, 1.26–3.80). For specific cancer types, we found increased risks for leukemias (RR = 1.65; 95% CI, 1.35–2.01), neuroblastomas (RR = 4.04; 95% CI, 1.24–13.18), and retinoblastomas (RR = 1.62; 95% CI, 1.12–2.35) associated with fertility treatment.

Conclusion(s)
The results of the largest meta-analysis on this topic to date indicate an association between fertility treatment and cancer in offspring. However, our results do not rule out that factors related to underlying subfertility, rather than the procedure itself, are the most important predisposing factors for childhood cancer.

Sadly for many DES daughters having their own children is not possible! Many of us who have experienced miscarriages, want to have kids but are struggling or unable to…
More about DES pregnancy risks. DES studies on fertility and pregnancy.

The European Food Safety Authority’s Independence Problem

More than half of experts at the EU food safety authority have conflicts of interest

The European Food Safety Authority's independence problem
European Food Safety Authority says it’s “Committed to ensuring that Europe’s food is safe”

Almost 60% of experts sitting on the European Food Safety Authority’s (EFSA) panels have direct or indirect links with industries regulated by the agency, according to an independent screening performed by Corporate Europe Observatory (CEO) – an advocacy group that criticizes corporate influence on public policy – and Stéphane Horel – freelance journalist and documentarian.

The CEO October 2013 report identifies major loopholes in EFSA’s independence policy and finds that EFSA’s new rules for assessing its experts, implemented in 2012 after several conflicts of interest scandals, have failed to improve the situation.

The authors warn that this situation casts a severe doubt on the credibility of the scientific output of the key body responsible for food safety at the EU, with the agency issuing recommendations and risk assessments on crucial public health issues such as food additives, packaging, GMOs, contaminants and pesticides.

The main loophole identified in EFSA’s new rules for assessing its experts’ interests is that the agency’s assessment is too narrow, mainly looking at the panel’s specific remit to determine whether there are conflicts of interest. Instead it should consider experts’ wider conflicts of interest, in line with the agency’s broader mandate to guarantee its decisions remain independent from the industry it regulates. The current approach enables dozens of experts with multiple commercial interests (consultancy contracts, research funding, etc) to still be granted full membership of EFSA panels, including a majority of panel chairs and vice-chairs.

The CEO report also shows that EFSA failed to properly implement its own new rules in several instances, and that there is no visible difference between panels assembled under the new policy and those composed using the old policy.

My Virginia, deeply affecting and genuinely funny Journey

Darci Picoult is a Journalist and DES Daughter

My Virginia, by Darci Picoult, on Flickr
My Virginia, Darci childhood name for “my vagina”

A deeply affecting and genuinely funny journey through the medical juggernaut of DES, and anti-miscarriage drug given to millions of pregnant women and later discovered to cause cancer and reproductive problems in their children.
Darci Picoult as journalist and DES daughter reveals the strength of mothers and daughters fighting together for their lives with guts, humor and love.
A one-woman performance featuring Darci Picoult.

More DES DiEthylStilbestrol Resources

Incidence of Breast Cancer with distant Involvement among Women in the United States, 1976 to 2009

JAMA, February 27, 2013

Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009
The Journal of the American Medical Association, published since 1883, is an international peer-reviewed general medical journal published 48 times per year

Importance:
Evidence from the US National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database suggests that the incidence of advanced breast cancer in young women is increasing.

Objective:
To quantify this trend and analyze it as a function of stage at diagnosis, race/ethnicity, residence, and hormone receptor status.

Design, Setting, and Patients:
Breast cancer incidence, incidence trends, and survival rates as a function of age and extent of disease at diagnosis were obtained from 3 SEER registries that provide data spanning 1973-2009, 1992-2009, and 2000-2009. SEER defines localized as disease confined to the breast, regional to contiguous and adjacent organ spread (eg, lymph nodes, chest wall), and distant disease to remote metastases (bone, brain, lung, etc).

Main Outcome Measure:
Breast cancer incidence trends in the United States.

Results:
In the United States, the incidence of breast cancer with distant involvement at diagnosis increased in 25- to 39-year-old women from 1.53 (95% CI, 1.01 to 2.21) per 100 000 in 1976 to 2.90 (95% CI, 2.31 to 3.59) per 100 000 in 2009. This is an absolute difference of 1.37 per 100 000, representing an average compounded increase of 2.07% per year (95% CI, 1.57% to 2.58%; P < .001) over the 34-year interval. No other age group or extent-of-disease subgroup of the same age range had a similar increase. For 25- to 39-year-olds, there was an increased incidence in distant disease among all races and ethnicities evaluated, especially non-Hispanic white and African American, and this occurred in both metropolitan and nonmetropolitan areas. Incidence for women with estrogen receptor–positive subtypes increased more than for women with estrogen receptor–negative subtypes.

Conclusion and Relevance:
Based on SEER data, there was a small but statistically significant increase in the incidence of breast cancer with distant involvement in the United States between 1976 and 2009 for women aged 25 to 39 years, without a corresponding increase in older women.

In the United States, breast cancer is the most common malignant tumor in adolescent and young adult women 15 to 39 years of age, accounting for 14% of all cancer in men and women in the age group.1 The individual average risk of a woman developing breast cancer in the United States was 1 in 173 by the age of 40 years when assessed in 2008.2 Young women with breast cancer tend to experience more aggressive disease than older women and have lower survival rates.2,3 Given the effect of the disease in young people and a clinical impression that more young women are being diagnosed with advanced disease, we reviewed the national trends in breast cancer incidence in the United States.

Additional Information – Full Study: Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009, JAMA, February 27, 2013, Vol 309, No. 8.

All our posts tagged Breast Cancer.

DES and Breast Cancer: